Tags : Chronic Fibrosing Interstitial Lung Disease

Boehringer Ingelheim Reports Results of OFEV (nintedanib) in P-III INBUILD

Vartika Singh October 10, 2019

Shots: The P-III INBUILD trial involves assessing of OFEV vs PBO in patients with chronic fibrosing interstitial lung disease (ILDs) with signs of progression for 52 wks. P-III INBUILD study […]readmore

Tags : Chronic Fibrosing Interstitial Lung Disease

Boehringer Ingelheim Reports Results of OFEV (nintedanib) in P-III INBUILD

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Chronic Fibrosing Interstitial Lung Disease

Boehringer Ingelheim Reports Results of OFEV (nintedanib) in P-III INBUILD

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company